NL-OMON56411
Recruiting
Not Applicable
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) - DETECT ASCEND 2
Exact Sciences Thrive LLC0 sites294 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- single blood draw for early detect of cancer
- Sponsor
- Exact Sciences Thrive LLC
- Enrollment
- 294
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All subjects
- •1\. \>\=50 years of age
- •2\. Subject understands the study procedures and is able to provide informed
- •consent to participate in the study and authorization for release of relevant
- •protected health information to the study investigator.
- •Cancer Subjects Only
- •3\. Subject has an untreated primary malignancy of breast, lung, colorectal,
- •prostate, bladder, uterine, kidney/renal pelvis, pancreatic, liver, stomach,
- •ovarian, esophageal cancer, head and neck squamous cell, thyroid, small
- •intestine, cervical, anal, vulva, or testis confirmed through pathology reports
Exclusion Criteria
- •1\. Prior or concurrent cancer diagnosis defined as:
- •a. Any previous cancer diagnosis within the past 5 years (with the exceptions
- •of basal cell or squamous cell skin cancers); OR
- •b. Recurrence of the same primary cancer within any timeframe; OR
- •c. Concurrent diagnosis of multiple primary cancers
- •2\. Chemotherapy and/or radiation therapy within 5 years prior to
- •enrollment/sample collection.
- •3\. Any treatment for the primary malignancy or sites of metastases. Subject may
- •not have started neo\-adjuvant chemotherapy, neo\-adjuvant radiation therapy,
- •immunotherapy or other treatment and/or surgery prior to blood sample
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND2)breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, uterine cancer, kidney/renal pelvis cancer, pancreatic cancer, liver cancer, stomach cancer, ovarian cancer, esophageal cancer, head and neck squamous cell cancer, thyroid cancer, small intestine cancer, cervical cancer, anal cancer, vulva cancer, testicular cancerDRKS00032437Exact Sciences Thrive LLC106
Completed
Not Applicable
Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK TestingEarly Cancer DetectionNCT04213326Exact Sciences Corporation6,400
Not yet recruiting
Not Applicable
A simple blood test to understand presence or absence of cancerCTRI/2023/04/052111Epigeneres Biotech Pvt Ltd
Completed
Not Applicable
Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinomaC25Malignant neoplasm of pancreasDRKS00023929Allgemein- und Viszeralchirurgie Uniklinik Freiburg14
Recruiting
Not Applicable
Development of early cancer diagnosis technique using blood sample by Raman spectroscopyJPRN-UMIN000034306Showa University Koto Toyosu Hospital2,000